Optimal Balance Pharmacy in Houston announced August 19 that it is voluntarily recalling one lot of Compounded Glutathione 200 mg/mL 30 mL Multi-Dose Vials to the patient level after in-house testing detected elevated bacterial endotoxin. The FDA published the notice August 20. Lot LG342009076, expiring October 4, 2026, had shipped to patients in fourteen states. Fourteen days earlier, Austin-based Victory Medical Center Pharmacy pulled three lots of the same concentration for the same contaminant. Two separate Texas compounding pharmacies failing on the same endotoxin assay within two weeks has directed scrutiny at the bulk glutathione powder entering the supply chain and at a federal framework that governs the ingredient under a dietary-supplement monograph rather than a pharmaceutical one.
The company's risk statement says injectable products carrying elevated endotoxin levels present a "reasonable probability of causing significant medical events, including fevers, low blood pressure, inflammatory reactions, anaphylactic shock, and death," according to the FDA recall announcement. Optimal Balance has logged adverse-event reports describing fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with an allergic reaction. No hospitalizations or deaths have been disclosed for this lot.
Fourteen days, two pharmacies, one contaminant
Victory Medical Center Pharmacy announced its recall on August 5, covering three lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials distributed in Texas, Florida, and New York. The Austin pharmacy reported patient complaints of fever, chills, rapid heart rate, and blood-pressure changes. Bloomberg reported that the action added to scrutiny of a rapidly expanding market for injectable peptides. Both pharmacies identified the contamination through their own quality testing, not through an FDA inspection or a patient complaint that triggered agency action.
Endotoxin is a structural component of the outer membrane of gram-negative bacteria. Standard autoclaving does not reliably destroy it, meaning a vial can pass a sterility culture and still deliver a hazardous endotoxin dose intravenously. The distinction matters for anyone evaluating compounded injectables: HPLC peptide testing confirms identity and purity but does not substitute for a dedicated endotoxin assay such as the Limulus amebocyte lysate test.
The 2019 warning and the supplement-grade supply chain
The mechanism behind both recalls has a documented precedent. In February 2019, the FDA warned compounders not to use glutathione powder distributed by Letco Medical of Decatur, Alabama, to compound sterile injectable drugs. Agency laboratory testing found excessive bacterial endotoxin in the powder—some results as high as five times the limit calculated for the intravenous dose those patients received—and the powder carried a dietary-supplement caution label indicating it was not intended for injection. Seven patients at an outpatient clinic who received intravenous L-glutathione developed nausea, vomiting, lightheadedness, and chills within minutes; one was hospitalized with low blood pressure and difficulty breathing. The FDA compounding alert noted that Letco had supplied the powder to roughly 100 compounders across 30 states.
Glutathione does not appear on the FDA's 503A or 503B bulk-substance lists for compounding, and the agency has not reviewed or approved any injectable version for safety or effectiveness. The ingredient is governed by a dietary-supplement monograph that sets purity standards for oral ingestion, not intravenous administration. Whether research peptides are safe in these compounding channels depends partly on whether the pharmacy sources pharmaceutical-grade bulk and runs a batch-level endotoxin assay—steps the current framework does not uniformly mandate.
Optimal Balance is notifying prescribers and patients by telephone and mail, arranging retrieval, and offering full refunds through its question line at (218) 919-2964. The FDA assigns recall classifications in its weekly enforcement reports; the agency has not yet posted a classification for the Optimal Balance lot or announced an inspection of the Houston facility beyond publishing the recall. The supplier of the bulk glutathione powder used by either pharmacy has not been publicly identified, and whether the two recalls trace to a common ingredient source remains unconfirmed.
